Angèle Consoli

Bio: Angèle Consoli is an academic researcher from Pierre-and-Marie-Curie University. The author has contributed to research in topics: Catatonia & Population. The author has an hindex of 25, co-authored 68 publications receiving 1744 citations. Previous affiliations of Angèle Consoli include University of Picardie Jules Verne & Paris Descartes University.

Auto-immunité et psychiatrie de l’enfant et de l’adolescent

Abstract: Resume Les pathologies auto-immunes sont de plus en plus observees, decrites et reconnues chez les enfants et les adolescents, que ce soit des maladies comme le lupus erythemateux dissemine (LED), les thyroidites auto-immunes, ou les encephalites auto-immunes dont les formes sont volontiers plus severes et plus agressives que celle decrites chez l’adulte. L’aspect psychiatrique de ces tableaux cliniques est souvent au premier plan. En effet, les symptomes psychiatriques sont nombreux, aigus, severes, ubiquitaires et pour la plupart atypiques. En consequence, de nombreux patients atteints de pathologies auto-immunes sous-jacentes sont pris en charge en pedopsychiatrie devant l’apparition brutale et bruyante de symptomes psychiatriques. Parmi ces symptomes figure la catatonie de l’enfant et l’adolescent qui prend une place particuliere. L’objet de cet article est de presenter des exemples de pathologies auto-immunes pouvant conduire a des tableaux psychiatriques chez l’enfant et l’adolescent, a travers une revue de la litterature. Nous detaillerons egalement le type de symptomes neuropsychiatriques rencontres dans ces pathologies auto-immunes, ainsi que le role important de la catatonie comme symptome de « porte d’entree ». Puis enfin nous aborderons les aspects et les enjeux diagnostiques et therapeutiques de ces pathologies. Notre discussion est illustree par deux vignettes cliniques.

Traitements des troubles bipolaires de type I de l'enfant et de l'adolescent

Abstract: Resume L'existence du trouble bipolaire type I de l'adolescent est aujourd'hui bien etabli. En revanche, la realite nosographique des formes prepuberes est plus controversee. Nous avons revu l'ensemble de la litterature sur les traitements curatifs et prophylactiques du trouble bipolaire infantojuvenile. Si dans la litterature, les recommandations suivent celles utilisees dans le traitement du trouble bipolaire de l'adulte, elles ne s'appuient pas sur des etudes controlees randomisees contre placebo specifiques au sujet jeune puisque nous n'avons trouve que deux etudes portant sur le lithium dans la litterature. Il apparait donc legitime de soutenir l'idee que la prescription soit limitee aux formes les plus typiques car l'interet des traitements utilises dans le trouble bipolaire de l'adulte chez l'enfant et l'adolescent apparait limite en cas de comorbidite au trouble hyperactivite avec deficit de l'attention en particulier.

Correction to: Repeating a suicide attempt during adolescence: risk and protective factors 12 months after hospitalization

Abstract: In the original article, incorrect Table 1 was published. The correct Table 1 is given below.

Down syndrome regression disorder, a case series: Clinical characterization and therapeutic approaches

Abstract: Down syndrome (DS) is one of the most frequent genetic disorders and represents the first cause of intellectual disability of genetic origin. While the majority of patients with DS follow a harmonious evolution, an unusual neurodevelopmental regression may occur, distinct from that described in the context of autism spectrum disorders, called down syndrome regression disorder (DSRD). Based on four patients, two males and two females, with age range between 20 and 24, treated at the Reference Center for Rare Psychiatric Disorders of the GHU Paris Psychiatry and Neurosciences [Pôle hospitalo-universitaire d’Évaluation Prévention et Innovation Thérapeutique (PEPIT)], we describe this syndrome, discuss its etiologies and propose therapeutic strategies. DSRD often occurs in late adolescence. There is a sudden onset of language disorders, loss of autonomy and daily living skills, as well as behavioral symptoms such as depression, psychosis, or catatonia. These symptoms are non-specific and lead to an overlap with other diagnostic categories, thus complicating diagnosis. The etiologies of the syndrome are not clearly identified but certain predispositions of patients with trisomy 21 have suggested an underlying immune-mediated mechanism. Symptomatic therapeutic approaches (serotonergic antidepressants, atypical antipsychotics, benzodiazepines) were not effective, and generally associated with poor tolerance. Etiological treatments, including anti-inflammatory drugs and corticosteroids, led to partial or good recovery in the four cases. Early recognition of regressive symptoms and rapid implementation of adapted treatments are required to improve the quality of life of patients and their families.

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

Abstract: The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain largely unchanged. Lithium, valproate, and several atypical antipsychotic agents continue to be first-line treatments for acute mania. Monotherapy with asenapine, paliperidone extended release (ER), and divalproex ER, as well as adjunctive asenapine, have been added as first-line options.For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first-line options. Lurasidone monotherapy and the combination of lurasidone or lamotrigine plus lithium or divalproex have been added as a second-line options. Ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have been added as not-recommended options for the treatment of bipolar depression. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long-acting injection, and adjunctive ziprasidone continue to be first-line options for maintenance treatment of bipolar disorder. Asenapine alone or as adjunctive therapy have been added as third-line options.

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

Abstract: The Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder in 2005, with a 2007 update. This second update, in conjunction with the International Society for Bipolar Disorders (ISBD), reviews new evidence and is designed to be used in conjunction with the previous publications. The recommendations for the management of acute mania remain mostly unchanged. Lithium, valproate, and several atypical antipsychotics continue to be first-line treatments for acute mania. Tamoxifen is now suggested as a third-line augmentation option. The combination of olanzapine and carbamazepine is not recommended. For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first-line options. New data support the use of adjunctive modafinil as a second-line option, but also indicate that aripiprazole should not be used as monotherapy for bipolar depression. Lithium, lamotrigine, valproate, and olanzapine continue to be first-line options for maintenance treatment of bipolar disorder. New data support the use of quetiapine monotherapy and adjunctive therapy for the prevention of manic and depressive events, aripiprazole monotherapy for the prevention of manic events, and risperidone long-acting injection monotherapy and adjunctive therapy, and adjunctive ziprasidone for the prevention of mood events. Bipolar II disorder is frequently overlooked in treatment guidelines, but has an important clinical impact on patients' lives. This update provides an expanded look at bipolar II disorder.